Market Overview

UPDATE: Jefferies Downgrades Cepheid to Hold on Persistent Volatility

Share:
Related CPHD
Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases
Benzinga's Top Upgrades
Cepheid promotes COO to President (Seeking Alpha)

In a report published on Friday, Jefferies analyst Brandon Couillard downgraded Cepheid (NASDAQ: CPHD) from Buy to Hold and maintained a price target of $38.00.

In the report, Jefferies noted, "CPHD has placed >1,000 systems in HBDC (high burden & developing countries) markets, which now account for ~25% of its global installed base. We forecast $45M & $57M (+26%) of HBDC revenues in 2013 & 2014, respectively, which conservatively factors a flat reagent annuity trend. With only ~60% of eligible countries on board, incremental HBDC-related revenues should continue to augment CPHD's core growth trajectory for the foreseeable future, though quarterly volatility is likely to persist until the program matures to scale."

Cepheid closed on Thursday at $36.62.

Latest Ratings for CPHD

DateFirmActionFromTo
Feb 2016Stifel NicolausMaintainsBuy
Feb 2016BairdMaintainsOutperform
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Brandon Couillard JefferiesAnalyst Color Downgrades Analyst Ratings

 

Related Articles (CPHD)

Get Benzinga's Newsletters